Sponsor:
AstraZeneca
Code:
NCT05925803
Conditions
Systemic Sclerosis
Scleroderma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Anifrolumab (blinded)
Placebo (blinded)
Anifrolumab (unblinded, open label)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-04-09.